FCFernanda Ginebra Castillo-Velásquez

Fernanda Ginebra Castillo-Velásquez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fernanda Ginebra Castillo-Velásquez has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Optimising contraceptive counselling: insights for obesity and bariatric surgery patients

    by Julia C. Coronado-Arroyo, Jenyfer María Fuentes-Mendoza, Marcio Concepción-Zavaleta, Fernanda Ginebra Castillo-Velásquez, Diego Velarde-García, Juan Eduardo Quiroz-Aldave, Luis Concepción-Urteaga, José Paz-Ibarra

    Women with obesity and those undergoing bariatric surgery face unique challenges when selecting contraceptive methods due to metabolic alterations, surgical malabsorption, and increased thromboembolic risk. This narrative review aims to summarise current evidence and provide practical guidance for safe and effective contraceptive counselling in these populations. A comprehensive narrative search was conducted in PubMed, Scopus and Google Scholar up to May 2025 using terms related to 'contraception', 'obesity', and 'bariatric surgery'. Recent international guidelines and clinical studies were synthesised to identify evidence-based recommendations and knowledge gaps. Combined hormonal contraceptives are relatively contraindicated in women with obesity, particularly in those with additional cardiovascular risk factors. Long-acting reversible contraception (LARC) methods, including intrauterine devices and subdermal implants, demonstrate the highest safety and effectiveness. Progestogen-only methods may be appropriate alternatives, while oral routes are less reliable after malabsorptive procedures. Tailored contraceptive counselling is essential for women with obesity and post-bariatric surgery. Prioritising LARC options, assessing individual thrombotic and metabolic risk, and providing multidisciplinary follow-up can optimise reproductive health outcomes in this growing population.

  • Advances in regenerative cardiology: Stem cells versus bioartificial tissues

    by Jenyfer María Fuentes‐Mendoza, Juan Muñoz‐Moreno, Marcio Concepción‐Zavaleta, Luis Concepción‐Urteaga, José Paz‐Ibarra, Roger Gonzales‐Valdivieso, Fernanda Ginebra Castillo‐Velásquez, Angie Sofía Burgos‐Castillo, Regina Garza‐Boullosa, Vanesa Daniela Núñez‐Pérez

    Background: Cardiovascular disease (CVD) remains the leading cause of mortality worldwide. The human myocardium has a limited regenerative capacity, prompting the development of innovative strategies to restore cardiac function. Stem cells (SCs) and bioartificial tissues (BATs) have emerged as promising tools in regenerative cardiology for myocardial repair and functional recovery.Methods: This review analyzes current preclinical and clinical research focused on SC‐ and BAT‐based therapies for CR. Literature was identified through comprehensive database searches. Studies evaluating cardiomyocyte differentiation, integration into host tissue, vascularisation and electromechanical properties were selected. Emphasis was placed on therapeutic potential, safety and translational challenges.Results: SCs, including embryonic and mesenchymal stem cells, demonstrated potential to differentiate into cardiomyocyte‐like cells and contribute to myocardial restoration. When combined with biomaterial scaffolds or decellularized matrices, SCs showed improved survival, structural support, and functional integration. BATs, such as engineered heart tissue, replicated native myocardial architecture and supported synchronized contraction. Despite these advances, concerns persist regarding immunogenicity, arrhythmias, and long‐term efficacy. Technical hurdles in large‐scale production and personalised application remain unresolved.Conclusions: SC‐ and BAT‐based therapies offer innovative avenues for repairing damaged myocardium. Their application could revolutionise treatment strategies for heart failure and post‐infarction remodelling. However, clinical translation requires addressing immune compatibility, arrhythmic risk and manufacturing limitations. Interdisciplinary collaboration and regulatory standardisation are essential for their future clinical adoption.